Daily Brief Health Care: BioStem Technologies , Adicet Bio and more

• BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies.
• The company announced testing results for its core BioRetain technology that showed the superiority of the treatment over the traditional standard of care.
• Additionally, the company received national pricing from Medicare for its Vendaje AC product.

• Adicet Bio is a biotech company working on developing an off-the-shelf CD20 gamma delta CAR-T cell therapy for autoimmune diseases, particularly lupus nephritis
• The company also has gamma delta CAR-T programs targeting various cancers, with value inflection data points expected in 2024 and 2025
• Despite trading at a negative enterprise value, Adicet has significant cash reserves and a manageable quarterly spend, making its equity potentially underpriced compared to peers, with the potential success of its autoimmune program leading to a stock re-rating.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.